The FDA has approved two new devices for heart rhythm disorder patients, which offer continuous remote-monitoring capabilities.
The agency approved Abbott's Gallant implantable cardioverter defibrillator and cardiac resynchronization therapy defibrillator devices. The devices can help cut the risk of abnormal heart rhythms and restore the natural patterns of heart rhythms.
The devices also pair with Abbott's myMerlinPulse application, which allows physicians to continuously monitor their patients remotely and provides access to data. The smartphone app is compatible with both Apple and Android phones.